An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics.

ABSTRACT: Next-generation multi-specific antibody therapeutics (MSATs) are engineered to combine several functional activities into one molecule to provide higher efficacy compared to conventional, mono-specific antibody therapeutics. However, highly engineered MSATs frequently display poor yields and less favorable drug-like properties (DLPs), which can adversely affect their development. Systematic screening of a large panel of MSAT variants in very high throughput (HT) is thus critical to identify potent molecule candidates with good yield and DLPs early in the discovery process. Here we report on the establishment of a novel, format-agnostic platform process for the fast generation and multiparametric screening of tens of thousands of MSAT variants. To this end, we have introduced full automatio

SUBMITTER: Furtmann N 

PROVIDER: S-EPMC8366542 | biostudies-literature | 2021 Jan-Dec

REPOSITORIES: biostudies-literature